Dentsply Sirona (NASDAQ:XRAY) Beats Q2 CY2026 Sales Expectations
Dentsply Sirona (NASDAQ:XRAY) reported Q2 CY2026 revenue of $898 million, down 4.1% year over year but 0.6% above market expectations. Full-year revenue guidance is $3.55 billion at the midpoint, about 1% below analysts’ estimates. Non-GAAP EPS was $0.52, 50.1% above consensus. Shares rose 1.8% to $13.42 after the release.
How this was made
The 30-second read
Why it matters
Traders can reassess valuation and forward expectations using the specific Q2 beat (revenue and EPS) alongside the slightly conservative full-year revenue guidance and Q2 adjusted operating margin contraction.
Market read
A mixed earnings-and-guidance print: Q2 revenue and EPS beat, but full-year revenue guidance is 1% below analysts’ estimates, with profitability pressure shown by margin contraction.
What to watch
The article highlights margin and revenue declines but does not break out segment performance, geographic mix, or order backlog, which could explain whether the revenue weakness is temporary.
Background
Dentsply Sirona is executing a Return-to-Growth Action Plan as it reports Q2 CY2026 results and issues full-year revenue guidance.
Ticker impact
Dentsply Sirona reported Q2 CY2026 revenue of $898M, down 4.1% YoY, but beating estimates, with full-year revenue guidance $3.55B at the midpoint.
Near-term volatility likely, with upside support from EPS beat and guidance EPS strength offset by revenue-guidance miss and margin pressure.
The article provides specific Q2 results (revenue, EPS) plus full-year revenue guidance versus estimates and notes adjusted operating margin contraction, which typically drives mixed post-earnings positioning.
Market effects
Dental/healthcare medtech demand and margin trends may be read through as investors assess whether cost discipline is offsetting weaker top-line growth.
Primarily US-listed healthcare sentiment; limited direct regional spillover implied by the article.
Global dental equipment demand is referenced, but no international regulatory or macro shock is disclosed.
Counterpoint
The revenue miss versus estimates may be less important if EPS guidance strength and cost control indicate earnings quality is improving despite softer sales.
Key entities
- companyDentsply Sirona
Reported Q2 CY2026 results, including revenue of $898M and non-GAAP EPS of $0.52, and guided full-year revenue to $3.55B at the midpoint.
- executiveDan Scavilla
President and CEO, quoted on executing the Return-to-Growth Action Plan.
